Hypoxia inducible factor (HIF) in rheumatology: Low O2! See what HIF can do!

Annals of the Rheumatic Diseases

Volumn 64, Issue 7, 2005, Pages 971-980

  Gaber, T ^a   Dziurla, R ^a   Tripmacher, R ^a   Burmester, G R ^a   Buttgereit, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CELECOXIB; CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOSTATIN; ETANERCEPT; FUMAGILLOL CHLOROACETYLCARBAMATE; GL 331; GLUCOCORTICOID; GOLD DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IBUPROFEN; INDOMETACIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 4; KETOROLAC; METHOTREXATE; MINOCYCLINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PENICILLAMINE; PIMONIDAZOLE; PX 478; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SEMAXANIB; THALIDOMIDE; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TX 402; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; CARDIOVASCULAR RISK; CARTILAGE DEGENERATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; ENERGY METABOLISM; GENETIC TRANSCRIPTION; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; NONHUMAN; OSTEOPOROSIS; OXYGEN CONCENTRATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SUPERINFECTION; SYNOVIUM; SYSTEMATIC REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANOXIA; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CELL HYPOXIA; CYCLOSPORINE; DNA-BINDING PROTEINS; GENE THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; OXYGEN; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21344453775     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.031641     Document Type: Review

References (119)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Falchuk KH, Goetzl EJ, Kulka JP. Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. Am J Med 1970;49:223-31.
3. Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum 1970;13:769-76.
4. Treuhaft PS, DJ MC. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum 1971;14:475-84.
5. Ahlqvist J. A hypothesis on the pathogenesis of rheumatoid and other non-specific synovitiaes. IV A. The possible intermediate role of local hypoxia and metabolic alterations. Med Hypotheses 1984;13:257-302.
6. Naughton DP, Haywood R, Blake DR, Edmonds S, Hawkes GE, Grootveld M. A comparative evaluation of the metabolic profiles of normal and inflammatory knee-joint synovial fluids by high resolution proton NMR spectroscopy. FEBS Lett 1993;332:221-5.
7. Peters CL, Morris G, Mapp PI, Blake DR, Lewis CE, Winrow VR. The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum 2004;50:291-6.
8. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Cnem 1993;268:21513-18.
9. Katschinski DM, Le L, Heinrich D, Wagner KF, Hofer T, Schindler SG, et al. Heat induction of the unphosphorylatea form of hypoxia-inducible factor-1 alpha is dependent on heat shock protein-90 activity. J Biol Chem 2002;277:9262-7.
10. Mekhail K, Gunaratnam L, Bonicalzi ME, Lee S. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol 2004;6:642-7 [Epub 6 June 2004].
11. Petersen W, Varaga D, Zantop T, Hassenpflug J, Mentlein R, Pufe T. Cyclic strain influences the expression of the vascular endathelial growth factor (VEGF) and the hypoxia inducible factor 1 alpha (HIF-1 alpha) in tendon fibroblasts. J Orthop Res 2004;22:847-53.
12. Pufe T, Lemke A, Kurz B, Petersen W, Tillmann B, Grodzinsky AJ, et al. Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol 2004;164:185-92.
13. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J 1998;17:5085-94.
14. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation or hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999;59:3915-18.
15. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999;94:1561-7.
16. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1alpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002;512:157-62.
17. Haddad JJ, Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha. FEBS Lett 2001;505:269-74.
18. Haddad JJ. Recombinant human interleukin (IL)-1 beta-mediated regulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilization, nuclear translocation and activation requires an antioxidant/reactive oxygen species (ROS)-sensitive mechanism. Eur Cytokine Netw 2002;13:250-60.
19. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfonnschmidt U, Roth U, Brandes RP, et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: role of the p22(phox)-containing NADPH oxidase. Circ Res 2001;89:47-54.
20. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J Biol Cnem 2000;275:26765-71.
21. Hollander AP, Corke KP, Freemont AJ, Lewis CE. Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001;44:1540-4.
22. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, El-Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002;46:2587-97.
23. Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, et al. Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003;5:R193-201.
24. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y, et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 2003;171:6534-40.
25. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
26. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-14.
27. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 1997;272:8581-93.
28. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7.
29. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
30. Iyer NV, Leung SW, Semenza GL. The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics 1998;52:159-65.
31. O'Rourke JF, Tian YM, Ratcliffe PJ, Pugh CW. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. J Biol Chem 1999;274:2060-71.
32. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-13.
33. Hara S, Hamada J, Kobayashi C, Kondo Y, Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun 2001;287:808-13.
34. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4.
35. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002;277:32405-8.
36. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987-92.
37. Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997;272:19253-60.
38. Carrero P, Okamoto K, Coumailleau P, O'Brien S, Tanaka H, Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol 2000;20:402-15.
39. Ruas JL, Poellinger L, Pereira T. Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation. Identification or amino acid residues critical for transcriptional activation and/or interaction with CREB-binding protein. J Biol Chem 2002;277:38723-30.
40. Gothie E, Richard DE, Berra E, Pages G, Pouyssegur J. Identification of alternative spliced variants of human hypoxia-inducible factor-1 alpha. J Biol Chem 2000;275:6922-7.
41. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci 2001;114(Pt 22):4051-61.
42. Chun YS, Choi E, Kim TY, Kim MS, Park JW. A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1alpha gene. Biochem J 2002;362(Pt 1)71-9.
43. Chun YS, Lee KH, Choi E, Bae SY, Yeo EJ, Huang LE, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res 2003;63:8700-7.
44. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood 1998;92:2260-8.
45. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, et al. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003;278:11032-40.
46. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and aestabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002;111:709-20.
47. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
48. Yuan Y, Hilllard G, Ferguson T, Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem 2003;278:15911-16.
49. Leung SK, Ohh M. Playing tag with HIF: the VHL story. J Biomed Biotechnol 2002;2:131-5.
50. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolylhydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 alpha in normoxia. Embo J 2003;22:4082-90.
51. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
52. Isaacs JS, Jung YJ, Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1 alpha by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 2004;279:128-35.
53. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 2001;15:2675-86.
54. Dial R, Sun ZY, Freedman SJ. Three conformational states of the p300 CH1 domain define its functional properties. Biochemistry 2003;42:9937-45.
55. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 2002;99:5367-72.
56. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. Structural basis for Hif-1 alpha /CBP recognition in me cellular hypoxic response. Proc Natl Acad Sci USA 2002;99:5271-6.
57. Merzen E, Berchner-Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M, et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 2003;116(Pt 7): 1319-26.
58. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002;295:858-61.
59. Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C. Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 2003;194:30-44.
60. Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C. ERK and calcium in activation of HIF-1. Ann N Y Acad Sci 2002;973:448-53.
61. Hofer T, Desbaillets I, Hopfl G, Gassmann M, Wenger RH. Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1 alpha activation cascade: implications for HIF-1alpha gene therapy. Faseb J 2001;15:2715-17.
62. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003;278:14013-19.
63. Chang H, Shyu KG, Wang BW, Kuan P. Regulation of hypoxia-inducible factor-1alpha by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci (Lond) 2003;105:447-56.
64. Kim CH, Cho YS, Chun YS, Park JW, Kim MS. Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 2002;90:E25-33.
65. Laughner E, Toghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001;21:3995-4004.
66. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541-5.
67. Zundel W, Schindler C, Haas-Koqan D, Koong A, Kaper F, Chen E, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000;14:391-6.
68. Sandau KB, Zhou J, Kietzmann T, Brune B. Regulation of the hypoxia-inducible factor 1 alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 2001;276:39805-11.
69. Zhou J, Schmid T, Frank R, Brune B. PI3K/Akt is required for heat shock proteins to protect HIF-1alpha from pVHL-independent degradation. J Biol Chem 2004;279:13506-13 [Epub 15 January 2004].
70. Iyer NV, Kotch LE, Agani F, Leunq SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149-62.
71. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359-69.
72. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol 1999;209:254-67.
73. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. Embo J 1998;17:3005-15.
74. Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001;15:2865-76.
75. Tomita S, Ueno M, Sakamoto M, Kitahama Y, Ueki M, Maekawa N, et al. Defective brain development in mice lacking the Hif-1 alpha gene in neural cells. Mol Cell Biol 2003;23:6739-49.
76. Chen J, Lansford R, Stewart V, Young F, Alt FW. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. Proc Natl Acad Sci USA 1993;90:4528-32.
77. Kojima H, Gu H, Nomura S, Caldwell CC, Kobata T, Carmeliet P, et al. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci USA 2002;99:2170-4.
78. Kojima H, Sitkovsky MV, Cascalho M. HIF-1 alpha deficiency perturbs T and B cell functions. Curr Pharm Des 2003;9:1827-32.
79. Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH. VhIh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol 2004;24:9038-47.
80. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 2003;278:13595-8.
81. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, et al. Hypoxia-inducible factor-1 alpha is a positive factor in solid tumor growth. Cancer Res 2000;60:4010-15.
82. Tak PP, Zvaifler NJ, Green DR, Firestein GS. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today 2000;21:78-82.
83. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485-95.
84. Albina JE, Mastofrancesco B, Vessella JA, Louis CA, Henry WL Jr, Reichner JS. HIF-1 expression in healing wounds: HIF-1alpha Induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol 2001;2B1:C1971-7.
85. Blades MC, Ingegnoli F, Wheller SK, Manzo A, Wahid S, Panayi GS, et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID Mice. Arthritis Rheum 2002;46:824-36.
86. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-8.
87. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 2001;107:305-15.
88. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10:858-64 [Epub 4 July 2004].
89. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307-11.
90. Kong T, Eltzschia HK, Karhausen J, Colgan SP, Shelley CS. Leukocyte adhesion during nypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc Natl Acsd Sci USA 2004;101:10440-5.
91. Sato Y. Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct Funct 2001;26:19-24.
92. Wernert N, Gilles F, Fafeur V, Bouali F, Raes MB, Pyke C, et al. Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. Cancer Res 1994;54:5683-8.
93. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K, Sata Y. Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 2001;289:39-43.
94. Paleolog EM. Angiogenesis in rheumatoid arthritis. Arthritis Res 2002;4(suppl 3):S81-90.
95. Takeda N, Maemura K, Imai Y, Harada T, Kawanami D, Nojiri T, et al. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, fetal liver tyrosine kinase 1. Circ Res 2004;95:146-53 [Epub 10 June 2004].
96. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62(suppl II):ii60-7.
97. Sandau KB, Fandrey J, Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 2001;97:1009-15.
98. Goyal P, Weissmann N, Grimminger F, Hegel C, Bader L, Rose F, et al. Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. Free Radic Biol Med 2004;36:1279-88.
99. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E. Interleukin induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000;350(Pt 1):307-12.
100. Blouin CC, Page EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1 {alpha}. Blood 2004;103:1124-30.
101. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1 alpha. Faseb J 2004;1B:382-4.
102. Taylor PC. VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res 2002;4(suppl 3):S99-107.
103. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999;115:176-82.
104. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, et al. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001;167:6140-9.
105. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, et al. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. Faseb J 2001;15:2445-53.
106. D'Angela G, Duplan E, Vigne P, Frelin C. Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1alpha Pro-564 hydroxylation. J Biol Chem 2003;278:15406-11.
107. Wang YQ, Luk JM, Ikeda K, Man K, Chu AC, Kaneda K, et al. Regulatory role of vHL/HIF-1 alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem Biophys Res Commun 2004;317:358-62.
108. Jones MK, Szabo IL, Kawanaka H, Husain SS, Tarnawski AS. von Hippel Lindau tumor suppressor and HIF-1 alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. Faseb J 2002;16:264-6.
109. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 2003;9:3150-7.
110. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, et al. Geldanamycin Induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
111. Nagasawa H, Mikamo N, Nakajima Y, Matsumoto H, Uto Y, Hori H. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. Anticancer Res 2003;23(6a):4427-34.
112. Neckers L. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 2003;10:733-9.
113. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3:233-44.
114. Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-54.
115. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003;95:516-25.
116. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002;196:204-12.
117. Matsuno H, Yudoh K, Uzuki M, Nakazawo F, Sawai T, Yamaguchi N, et al. Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J Rheumatol 2002;29:890-5.
118. Kurosaka D, Yoshida K, Yasuda J, Yokoyama T, Kingetsu I, Yamaguchi N, et al. Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann Rheum Dis 2003;62:677-9.
119. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004;13:649-63.